From our results it seems that the lower levels of both immune checkpoints in MM CD4 T cells suggest they are not appropriate targets for therapeutic inhibitors in MM, at least at disease onset, and, consequently, should not to be considered in first-line treatment settings. Here, CD4 is linked to Miyoshi myopathy.